Belite Bio is well-positioned with $780 million in cash and U.S. Treasuries as it prepares for the potential launch of tinlarebant, a novel treatment for Stargardt disease type 1, with an FDA decision expected by February 2027.
Read Full Story →
Belite Bio is well-positioned with $780 million in cash and U.S. Treasuries as it prepares for the potential launch of tinlarebant, a novel treatment for Stargardt disease type 1, with an FDA decision expected by February 2027.
Balfour Beatty's US and UK projects drive substantial revenue growth, highlighting strategic opportunities in construction.
Structure Tone, part of the US STO Building Group, reported significant revenue growth in 2025, with gross revenues reaching £448.8 million. Their secured workload now stands at £1.3 billion, indicating strong future growth prospects.
CF Industries' $1.3 billion CapEx plan for 2026 focuses on low-carbon ammonia and DEF expansion, opening opportunities for AECM and government contractors.
Silicon Motion's new MonTitan SSD RDK enhances AI workload efficiency with PerformaShape technology, crucial for AECM sectors seeking better data management and compliance.
Marshalls reports a 13.2% rise in profits despite a slight revenue decline, highlighting strategic cost management and operational focus. US AECM firms can glean insights on maintaining growth amidst market challenges.
Aspen Aerogels reports an 81% increase in Thermal Barrier revenue, driven by a major contract with Jaguar Land Rover. This highlights opportunities for AECM stakeholders in the EV sector.
Trekor Metals' Yellowhead project in BC targets 4.4 billion pounds of copper, with a potential $540 million tax credit. This development is crucial for US AECM stakeholders eyeing sustainable investments.
Moove's $250 million funding round aims to scale autonomous mobility infrastructure, presenting new opportunities and challenges for the AECM sector.
